For asthma and reversible bronchospasm associated with bronchitis and emphysema. ANDA 75877, held by Impax Labs. Terbutaline Sulfate.
As of Nov 16, 2026, ANDA 75877 (Terbutaline Sulfate), held by Impax Labs, was first approved by FDA on Jun 26, 2001, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Terbutaline sulfate tablets are indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 26, 2001 | Original application | Approved | None posted |
| Terbutaline Sulfate2.5MG · tablet;oral | Terbutaline Sulfate | Rx |
| Terbutaline Sulfate5MG · tablet;oral | Terbutaline Sulfate | Rx |
| Apr 8, 2011 | Supplement 1Labeling | Approved | None posted |
| Jun 26, 2001 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters